Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Wall Street Analyst Weigh In
Separately, Citigroup decreased their target price on Ovid Therapeutics to $2.40 and set a "neutral" rating for the company in a research note on Friday, May 20th.
Ovid Therapeutics Stock Performance
Ovid Therapeutics stock opened at $2.20 on Monday. Ovid Therapeutics has a 12 month low of $1.65 and a 12 month high of $4.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.63 and a current ratio of 16.63. The business has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $2.61.
Ovid Therapeutics (NASDAQ:OVID - Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $1.17 by ($1.40). The firm had revenue of $1.45 million during the quarter. Equities research analysts anticipate that Ovid Therapeutics will post -0.98 EPS for the current year.